Abstract
Rheumatoid Arthritis (RA) is an autoimmune disease characterized by persistent inflammation and joint damage. The main aim of RA treatment is to control the disease progress. Despite the success of biologicals like Adalimumab, Atlizumab, infliximab, etc. in treatment of RA, the high cost and associated immunological adverse effects have triggered discovery of small molecules targeting RA. This review describes the last 15 years of small molecular drug discovery in RA, focused mainly on preclinical and clinical studies.
Keywords: Janus kinase, peptidyl arginine deiminase, phosphoinositide 3-kinase, rheumatoid arthritis, TNFα-converting enzyme, Tyrosine kinase.
Mini-Reviews in Medicinal Chemistry
Title:Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Volume: 15 Issue: 2
Author(s): Vadiraj D. Kurdekar and Hemant R. Jadhav
Affiliation:
Keywords: Janus kinase, peptidyl arginine deiminase, phosphoinositide 3-kinase, rheumatoid arthritis, TNFα-converting enzyme, Tyrosine kinase.
Abstract: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by persistent inflammation and joint damage. The main aim of RA treatment is to control the disease progress. Despite the success of biologicals like Adalimumab, Atlizumab, infliximab, etc. in treatment of RA, the high cost and associated immunological adverse effects have triggered discovery of small molecules targeting RA. This review describes the last 15 years of small molecular drug discovery in RA, focused mainly on preclinical and clinical studies.
Export Options
About this article
Cite this article as:
Kurdekar D. Vadiraj and Jadhav R. Hemant, Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far, Mini-Reviews in Medicinal Chemistry 2015; 15 (2) . https://dx.doi.org/10.2174/1389557515666150101101850
DOI https://dx.doi.org/10.2174/1389557515666150101101850 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) 3D Structure Generation, Molecular Dynamics and Docking Studies of IRHOM2 Protein Involved in Cancer & Rheumatoid Arthritis
Current Computer-Aided Drug Design Progress in Studies of Structure, Mechanism and Antagonists Interaction of GPCR Co-Receptors for HIV
Current Pharmaceutical Biotechnology Gene Therapy Approaches for Cartilage Injury and Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Selection of Healthy Volunteers According to their Multidrug Resistance Protein 1 Activity Does Not Affect Bioavailability of Quetiapine
Current Psychopharmacology Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
Current Pharmaceutical Biotechnology Inflammation, Adipocytokines, and Atherosclerosis in the Metabolic Syndrome
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases
Current Vascular Pharmacology A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem
Current Drug Targets Immunoregulation Through 1,25-Dihydroxyvitamin D 3 and its Analogs
Current Drug Targets - Inflammation & Allergy Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Editorial: Pulmonary Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology